Despite a lack of confidence from investors, Mann believes his product will succeed and that the product could bring in more than $1 billion annually. One of the advantages of Technosphere is its fast absorption rate. Upon inhalation, the insulin reaches a peak bloodstream level in less than 15 minutes versus injectable products that can take up to 90 minutes. The safety issue will be critical to product approval. According to Mann, Technosphere is different than Pfizer's Exubera inhaled insulin (Six patients involved in the Exubera clinical trial developed lung cancer). He said that following the Pfizer report, an independent safety board found no signs of emerging lung cancer in MannKind's trials. And even if Technosphere is approved by FDA, market acceptance won't be quick or easy. Given past failures with inhaled insulin, investors won't have confidence in the product, and doctors will be faced with explaining a completely new way of taking insulin to patients. UPDATE: Pfizer and Mann collaborate.